ASCO 2018: Phase III Trial—Mogamulizumab Improves Quality of Life in Patients with Cutaneous T‑cell Lymphoma
The MAVORIC trial is the largest randomized trial and the first pivotal trial to use progression-free survival (PFS) as a primary endpoint in CTCL.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.